Haleon (LON:HLN) Shares Climb 2.7% – Here’s What Happened

Haleon plc (LON:HLN) shot up 2.7% on Thursday. The company traded as high as GBX 383.80 and last traded at GBX 382.70. Approximately 30,236,904 shares were traded during trading, an increase of 9% from the average daily volume of 27,777,375 shares. The stock had previously closed at GBX 372.60.

Analyst Ratings Changes

Several research firms have weighed in on HLN. Deutsche Bank Aktiengesellschaft lowered their price objective on Haleon from GBX 335 to GBX 320 and set a “sell” rating on the stock in a research report on Wednesday, September 9th. Royal Bank Of Canada boosted their target price on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research report on Tuesday, August 11th. Berenberg Bank increased their price target on Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 400 target price on shares of Haleon in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of GBX 387.80.

Haleon Stock Performance

The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The company has a market cap of £33.53 billion, a price-to-earnings ratio of 21.06, a P/E/G ratio of 1.49 and a beta of 0.24. The company has a fifty day moving average of GBX 352.93 and a two-hundred day moving average of GBX 351.20.

Haleon (LON:HLN) last issued its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. Equities research analysts anticipate that Haleon plc will post 19.50 EPS for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.